Effectiveness of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABItude study
- Procopio, Giuseppe
- Chiuri, Vincenzo Emanuele
- Giordano, Monica
- Mantini, Giovanna
- Maisano, Roberto
- Bordonaro, Roberto
- Calvani, Nicola
- Facchini, Gaetano
- De Placido, Sabino
- Airoldi, Mario
- Sbrana, Andrea
- Gasparro, Donatello
- Ludovico, Giuseppe Mario
- Guglielmini, Pamela
- Naglieri, Emanuele
- Fagnani, Daniele
- Aglietta, Massimo
- Schips, Luigi
- Beccaglia, Patrizia
- Sciarra, Alessandro
- Livi, Lorenzo
- Santini, Daniele
DOIAbstract
Real-world data on chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone plus prednisone are limited, largely deriving from small retrospective studies
Add to ORKG